To view the PDF file, sign up for a MySharenet subscription.

JDH - John Daniel Holdings Limited - Reviewed second interim financial

Release Date: 30/09/2011 12:38
Code(s): JDH
Wrap Text

JDH - John Daniel Holdings Limited - Reviewed second interim financial statements for the 12 months ended 30 June 2011 JOHN DANIEL HOLDINGS LIMITED Incorporated in the Republic of South Africa Registration number: 1998/013215/06 JSE Code: JDH - ISIN: ZAE000136677 ("the Company" or "JDH" or "the Group") REVIEWED SECOND INTERIM FINANCIAL STATEMENTS FOR THE 12 MONTHS ENDED 30 JUNE 2011 Reviewed Statement of Financial Position as at 30 June 2011 30 June 30 June 2011Reviewed 2010Audited
Group Group R`000 R`000 ASSETS Non-current assets Property, plant and equipment 2 332 3 204 Intangible assets 936 936 Deferred tax 4 455 3 365
Total current assets 1 932 1 270 TOTAL ASSETS 9 655 8 775
EQUITY AND LIABILITIES Equity (2 860) 1 170 Non-controlling interest (2 623) (433)
Non-current liabilities Interest bearing borrowings 7 534 121 Deferred tax - 182
Total current liabilities, short term interest bearing borrowings 7 604 7 735 and shareholders` loans
TOTAL EQUITY AND LIABILITIES 9 655 8 775 Net asset value (2 860) 1 170
Net tangible asset value (3 796) 234 Net asset value per share (cents) (1.90) 0.78
Net tangible asset value per share (2.52) 0.16 (cents) Reviewed Statement of Comprehensive Income for the 12 months ended 30 June 2011 30 June 30 June
2011Reviewed 2010Audited Group Group R`000 R`000
REVENUE 2 931 5 714 COST OF SALES (870) (4 093) GROSS PROFIT 2 061 1 621 Other income 546 125 Selling, distribution and (9 573) (10 811) administration expenses LOSS BEFORE NET FINANCE COSTS AND (6 966) (9 065) TAXATION Net Finance costs (525) (1 046) Taxation income 1 272 1 027 LOSS FOR THE YEAR (6 219) (9 084) Attributable to non-controlling 2 189 2 439 interest NET LOSS ATTRIBUTABLE TO ORDINARY (4 030) (6 645) SHAREHOLDERS
BASIC AND HEADLINE LOSS Basic loss (4 030) (6 645)
Headline loss (4 023) (5 503) Basic loss per share (cents) (2.68) (8.13) attributable to equity holders of the parent Headline loss per share (cents) (2.67) (6.74) attributable to equity holders of the parent Number of shares in issue 150 500 000 150 500 000
Weighted average number of shares 150 500 000 81 703 640 RECONCILIATION BETWEEN BASIC LOSS AND HEADLINE LOSS IAS 33 Basic loss (4 030) (6 645) IAS 16 Loss disposal of property 7 - plant and equipment IAS 36 Impairment of property, plant - 516 and equipment IAS 36 Impairment of intangible - 626 assets Headline Loss (4 023) (5 503) Reviewed Segmental Information for the 12 months ended 30 June 2011 The Group has adopted IFRS 8 Operating Segments as its segmental reporting standard which requires an entity to report financial and descriptive information about its reportable segments, which are operating segments or the aggregation of operating segments that meet specified criteria. Operating segments are components of an entity in respect of which separate financial information is available is evaluated regularly by management. R`000 R`000 R`000 R`000 R`000 30 June 2011 Biotech- Packag- Corpo- Elimin- Consoli-
nology ing rate ations dated Revenues 2 562 369 1 571 (1 571) 2 931 TOTAL 2 931 EXTERNAL REVENUE Operating (2 439) (2 477) (2 050) - (6 966) loss 30 June 2010 Biotech- Packag- Corpo- Elimin- Consoli-
nology ing rate ations dated Revenues 1 937 3 777 1 353 (1 353) 5 714 TOTAL 5 714 EXTERNAL REVENUE Operating (992) (6 369) (11 102) 9 398 (9 065) loss Reviewed Statement of Changes in Equity for the 12 months ended 30 June 2011 Share Non Accumul- Non- Total capital distribute- ated loss controlli equity
able ng reserves interest R`000 R`000 R`000 R`000 R`000
Balance at 1 24 415 7 729 (35 580) 2 007 (1 429) July 2009 Total - - (6 645) (2 439) (9 084) comprehensive loss for the year Issue of 11 893 - - - 11 893 shares Share issue (643) - - - (643) expenses Balance at 30 35 665 7 729 (42 225) (433) 736 June 2010 Total - - (4 030) (2 189) (6 219) comprehensive loss for the year Balance at 30 35 665 7 729 (46 255) (2 622) (5 483) June 2011 Reviewed Cash Flow Statement for the 12 months ended 30 June 2011 30 June 30 June 2011Reviewed 2010Audited
Group Group R`000 R`000 NET CASH (OUTFLOW)/INFLOW FROM (5 841) 21 OPERATING ACTIVITIES NET CASH INFLOW/ (OUTFLOW) FROM 430 (200) INVESTING ACTIVITIES NET CASH INFLOW/(OUTFLOW) FROM 5 530 (129) FINANCING ACTIVITIES
Increase / (Decrease) in cash and 119 (308) cash equivalents Cash and cash equivalents at the 34 342 beginning of the year Cash and cash equivalents at the end 153 34 of the year COMMENTARY REVIEW OF RESULTS AND FINANCIAL POSITION The reviewed consolidated financial results for the 12 months ended 30 June 2011 represents income and expenses from the JDH corporate head office and the group`s two trading subsidiaries, Vinguard Limited ("Vinguard") and Lazaron Biotechnologies (SA) Limited ("Lazaron"). The Group`s loss attributable to ordinary shareholders amounted to R4 million, a 39.4% reduction in the loss compared to the comparative period. The improved loss is attributable to a combination of the following factors: the reduction of the group finance costs resulting from the settlement, through a conversion to equity, of the Golden Oak Corporate Advisors (Pty) Ltd interest bearing loan account; and cost saving initiatives significantly reducing Vinguard`s operational expenses. The group operations experienced significant working capital constraints impacting on the trading performance of both subsidiaries. The impact of the working capital constraints resulted in a reduction of 48.7% in the group`s revenue. To alleviate the working capital constraints the previous board entered into a finance restructure agreement with Escalator Capital Limited ("Escalator") at the end of the first quarter of the period under review. (Refer Group restructure and recapitalisation below). Vinguard`s turnover for the 12 months reduced to R370 000, a 90% reduction compared to the previous 12 months. The majority of Vinguard`s sales are generated from mid-November during the South African table grape harvesting season. Unfortunately the Escalator funding, released to the business at end September 2010, was too late and was also limited, resulting in Vinguard being unable to secure raw materials in terms of the production schedules. The business was unable to produce SO2 sheets for distribution during the 2010/2011 South African season as well as for the traditional international markets. The new directors reduced overheads for the second six months under review in order to limit losses. This however incurred once off restructuring expenses. In comparison Lazaron`s revenue increased by 32% to R2.6 million. The increased sales performance was realised over the latter half of the 12 months under review due to the development of focused channels to market. During the first six months up to 31 December 2010 revenue was down by 7.4% compared to the comparative interim period. The cost of development of the sales channels increased overheads during the same period. The Group statement of financial position reflects a negative net asset value position due to the continued operating losses. The operating losses and Group restructure is being funded by Escalator through the finance restructure facility. The board obtained a letter of continued financial support from Escalator undertaking the continued funding of the restructuring process until the Group operations return to profitability. The sustainability of the group has in the short term been addressed through the increased funding. The directors are confident that the combination of the corporate restructuring, aggressive management of the existing subsidiaries and further strategic acquisitions will ensure the future sustainability of the group. In addition, on 10 June 2011, the directors announced two partially underwritten rights offers, in JDH for R15 million and in Lazaron for R4.4 million, to recapitalise the Group and return the statement of financial position to solvency. OPERATIONAL REVIEW Group Overview In the period under review JDH continued to conduct business as a venture capital investment holding company, and will continue to do so, focusing on investing in companies which are niche players and strategic in nature. Preference is given to companies which have clear African and Global markets. In particular, these companies are required to produce products or provide services with high barriers to entry and high gross profit margins. At 30 June 2011 JDH had two such subsidiaries, Lazaron and Vinguard. Vinguard The Vinguard product has proved its efficacy and table grape farmers reported excellent results on exports. The product is well placed to penetrate the significant South African and international export table grape industries. The company`s operations involve a relatively extended production and working capital cycle. The Group`s restrained working capital position and the resultant inability to fund production resulted in a significantly reduced market during the past SA season. The 90% reduction in turnover to R370 000 was off-set to an extent by the reduction in operating expenses resulting from the rationalization of the company`s operations. The company`s loss before non-controlling interest, which includes the once-off restructure expenses in the 12 months under review, reduced from R6.4 million to R2.7 million. The Vinguard cost structure and processes have been rationalized through the restructuring efforts ensuring that the breakeven point is achieved at a 33% reduced turnover value than in the comparative period. The business is poised to take advantage of its reduced overhead structure in the upcoming 2011/2012 SA table grape season. In addition, the board continues to drive efforts to diversify the Vinguard product offering into other produce markets as well as Northern Hemisphere production areas. Lazaron The establishment of a dedicated sales division in Lazaron as part of the group restructure resulted in significant sales growth for the business during the period under review. The 32% increase in the company`s revenue was generated in the last six months of the period under review. The accompanying cost involved in repositioning the strategic direction of the business, investing in marketing collateral, strategic initiatives and the development of the sales force increased the operating expense base. The company did not realise the full benefit of the investment during the period and as a result the company reported an increased loss of R1.96 million compared to R990 000 in the previous period. The encouraging sales performance and the healthy gross profit percentages resulted in the business approaching breakeven performance on a month to month basis by the end of the period under review. The restructure efforts focused on Lazaron and the resultant improved performance brought about the negotiations with Cryo-Save NV and the subsequent Cryo-Save SA joint venture announced at the end of the 12 month period, with an effective date of 1 July 2011. Subject to shareholder approval Lazaron will cease to provide a stem cell harvesting and storage service and these functions will be provided by the Cryo- Save SA joint venture laboratory in Belville, Cape Town. Lazaron will however continue to store the existing clients` samples generating annual storage income. The annuity income in Lazaron and its reduced cost base will result in the Lazaron business being profitable. EVENTS AFTER THE REPORTING PERIOD Corporate actions The new board, as detailed below, had been reviewing various options aimed at strengthening the Group`s statement of financial position. This process comprised continuing discussions with Escalator to renegotiate the terms of the Escalator loan including the possibility of Escalator underwriting a JDH Rights Offer. On 10 June 2011 the board announced the following partially underwritten rights offers: a R15 million JDH Rights Offer at 7 cents per share underwritten to the value of R10 million by Escalator; and a R4.4 million Lazaron Rights Offer underwritten to a minimum value of R1.5 million by JDH. The main objectives of the corporate actions are to recapitalise the Group and return the statement of financial position to solvency. The JDH Rights Offer has been approved by the JSE and the salient dates announced. The rights offer will close out on 14 October 2011. Shareholders` attention is drawn to the circular which has been issued and will be available on the Company`s website (www.john-daniel.com). The final salient dates for the Lazaron Rights Offer will be announced and a circular to Lazaron shareholders will be distributed as soon as the final approval is received from the Takeover Regulation Panel. Included in the Lazaron Rights Offer circular is a resolution for the proposed shareholder approval of the Section 112 disposal of the Lazaron sales infrastructure as well as some of the Lazaron laboratory equipment to JDH, which will on sell same to the Cryo-Save joint venture. This transaction removes all significant overheads from the Lazaron company. In addition, a General Offer to Lazaron non-controlling shareholders to swap their Lazaron shares for JDH shares is included in the corporate action. The swap provides Lazaron shareholders with incremental value and enhanced tradability. The Lazaron Rights Offer Circular will be available on the Company`s website. Cryo-Save South Africa - Joint Venture On 2 June 2011, the board announced that JDH and Cryo-Save Group N.V. ("Cryo- Save") a leading international family stem cell bank, signed a memorandum of understanding, to establish a new stem cell bank joint venture in South Africa. This joint venture will contain the South African sales and marketing operations of both companies and the Cape Town processing and storage facility of Lazaron and will immediately expand its operations into several African countries. The joint venture combines Cryo-Save`s leading expertise in stem cell processing and storage with JDH`s local and African market expertise. The joint venture will offer customers the option of storing cord tissue and stem cells from cord blood in South Africa or off shore in Belgium. The Lazaron laboratory located in Cape Town has been upgraded to cater for the increase in volumes and will meet the highest quality standards applied by Cryo- Save around the world. The joint venture will trade under the name Cryo-Save South Africa. The conditions precedent to concluding this joint venture and sale of businesses to the joint venture is subject to the approval of the company`s shareholders, directors and regulatory bodies, where applicable. Acquisition of a Micro-financing credit provider With effect from 01 July 2011, an agreement providing for the acquisition by JDH of 100% of the shares in, and claims against, Viscacom was signed for a cash consideration of R100. At the effective date, Viscacom had a loan of approximately R1.5 million owing to Escalator. This loan will be settled or capitilised through the JDH Rights Offer, either from cash received or through the Underwriting Agreement with Escalator. Viscacom is a micro finance organisation providing financial services to third party company employees and is the first acquisition by JDH in its new Financial Services Division. Viscacom was established in 2010 and has shown exponential growth since its incorporation. As at 30 June 2011 the company had over 200 clients and a loan book of R2.6 million. CONTINGENT LIABILITY A dispute with an off-shore supplier exists in terms of which the supplier is claiming an amount due of USD 464 126 ("disputed liability"). The statement of financial position has provided for an amount of USD 279 394, converted at the 30 June 2011 spot rate, in respect of this disputed liability. GROUP RESTRUCTURE AND RECAPITALISATION In September 2010 the Company entered into a finance restructure agreement with Escalator in terms of which the Company secured a convertible loan facility ("Escalator loan"). The conditions of the finance restructure agreement included the appointment of, inter alia, new executive directors, independent of Escalator, who were appointed to the Company board on 22 September 2010. All the previous board members resigned during the period September 2010 to November 2010. Three new independent non-executive directors, detailed below, were subsequently appointed to the board to complete the composition of the board ("new board"). The new board continues to review and evaluate Group operations and Group structures in order to steer the Group restructure with the objective of returning Group operations to profitability, both organically and acquisitively if necessary, thereby creating enhanced shareholder value. In terms of the Group restructure the board of directors was re-constituted and at the date of this announcement comprised: Name Designation Date Appointed TP Gregory Chief Executive Officer 22 September 2010 DP van der Merwe Financial Director 22 September 2010 B Topham Independent Non-Executive 24 November 2010 Director KA Rayner Independent Non-Executive 20 January 2011 Director
RJ Connellan Independent Non-Executive 03 February 2011 Director and Chairman The appropriate statutory documentation was submitted to both the JSE and CIPC to formally update the company records regarding the directors` changes. At the date of this announcement, only the appointments of TP Gregory and DP van der Merwe have been effected on the CIPC system. The board will continue to follow up with CIPC until the records are appropriately updated. The re-constitution of the board continues and an additional independent non- executive director will be appointed shortly. In addition, the board will also announce the appointment of a new company secretary. PROSPECTS The turnaround of current subsidiaries through product and market extension, aggressive trading and cost reduction continues. This includes the evaluation of product range extension in subsidiaries, development of new markets for subsidiaries and rationalization of administration and support structures. Ongoing shareholders support is required to continue to develop the current companies and look for new opportunities. The new board of directors is actively investigating acquisition opportunities that will improve earnings and cash generation for the group. It is the intention of the board to develop a robust and complementary group of companies which provide sustainable returns. YEAR END CHANGE JDH and its subsidiaries year ends have been changed to 30 September. The Group will report its next audited results for the 15 months ending 30 September 2011. The Second Interim Report will be available on the Company`s website. BASIS OF PREPARATION AND ACCOUNTING POLICIES The second interim financial statements have been prepared in accordance with IAS 34 - Interim Financial Reporting in accordance with the accounting policies that comply with International Financial Reporting Standards and in the manner required by the Companies Act (71 of 2008) and the JSE Listing Requirements. The principle accounting policies adopted in preparation of these financial statements are consistent with those of the prior period. REVIEW OPINION These results have been reviewed by the group`s auditors, AM Smith and Company Inc, whose modified review opinion, with an emphasis of matter is available for inspection at the company`s registered office. The emphasis of matter states that "without qualifying our opinion, we draw attention to the commentary which indicates that the company incurred a net loss of R4 029 558 after minority interest for the year ended 30 June 2011 and, as at that date, the Company`s total liabilities exceeded its total assets by R5 483 038. The commentary also indicates that these conditions along with other matters indicate the existence of a material uncertainty which may cast significant doubt on the company`s ability to continue as a going concern." ACQUISITIONS AND DISPOSALS There were no acquisitions or disposals during the 12 months under review. INCREASE IN AUTHORISED SHARE CAPITAL AND ISSUE OF SHARES During the period under review no new shares were issued and the issued share capital of the company was 150 500 000 ordinary shares and the authorised share capital was 150 000 000. At the Annual General Meeting of the Company held on 28 January 2011, a special resolution to increase the authorised share capital to 1 000 000 000 shares was passed by the requisite majority of shareholders. The special resolution has been submitted and lodged with CIPC. The previous board had issued 500 000 shares in excess of the authorised share capital and also committed to the issue of 5 290 023 shares as settlement of a current liability. Both these share issues were approved by shareholders during previous financial periods. The 500 000 and 5 290 023 shares were listed and issued in August 2011 to honour the Company`s commitments. DIVIDENDS No dividends have been declared and no dividend is proposed. GOING CONCERN The directors are of the opinion that the group will continue as a going concern for the foreseeable future due to the continued support of certain parties to the group and in particular by the holding company to its subsidiaries. The corporate actions referred to under "Events after the reporting period", are expected to restore the Group`s solvency and raise cash resources to support the continued turnaround of the Group operations. For and on behalf of the Board TP Gregory DP Van der Merwe (Preparer) Pretoria 30 September 2011 Directors: RJ Connellan* (Chairman), TP Gregory (Chief Executive Officer), DP van der Merwe (Financial Director), KA Rayner*, B Topham*. (* Independent Non- Executives) Company Secretary: DP van der Merwe Registered Office: Suite 4 Building 9, Tijger Valley Office Estate, Silver Lakes Road, Pretoria 0081, PO Box 39660, Garsfontein East 0060 Transfer Secretaries: Computershare Investor Services (Pty) Limited, 70 Marshall Street, Marshalltown 2001, PO Box 61051, Marshalltown 2107 Auditors: AM Smith and Company Inc Sponsor: Arcay Moela Sponsors (Pty) Limited Date: 30/09/2011 12:38:02 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story